Los Angeles Rams: “Thursday”
The Los Angeles Rams kick off the NFL Draft with help from some old neighborhood friends.
Global Institute of Stem Cell Therapy and Research
In May 2020, a class-action lawsuit was filed against Global Institute of Stem Cell Therapy and Research for allegedly:
- Misleadingly representing that its stem cell therapy treatment can treat multiple diseases – including sickle cell anemia, leukemia, lymphoma, and thalassemia – when, according to the complaint, the treatment does not treat such diseases and is not approved by the FDA;
- Failing to disclose the risks associated with the treatment;
- Making false statements about one of the co-founder’s education, academic appointments, and clinical experience; and
- Falsely claiming that the defendants are affiliated with and have stem cell clinics set up at reputable medical institutions when, according to plaintiffs, they are not affiliated with and do not have clinics at the institutions.
Plaintiffs also claim that the defendants are not licensed to perform stem cell treatments in the United States. (Mendez et al v. Global Institute of Stem Cell Therapy and Research USA et al, Case No. 20-cv-915, S.D. Cal.)
The Latest
On Shoes
Lawsuit pokes holes in company’s Swiss branding.
Junk Fees at JFK, LaGuardia and Newark Airports
Why are these airport vendors slyly charging consumers for “employee benefits”?
FTC Takes TruHeight’s Growth Claims Down a Few Pegs
Supplement maker agrees to pay $750K to settle deceptive health claims lawsuit.
FTC Cracks Down on Forever Living Following Years of Deception
Settlement comes after TINA.org exposed thousands of deceptive income claims.